Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Apr;175(4):W47-W48.
doi: 10.7326/L21-0791. Epub 2022 Feb 8.

Update Alert 9: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults

Katherine Mackey  1 , Devan Kansagara  1 , Kathryn Vela  1
Affiliations
Comment

Update Alert 9: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults

Katherine Mackey et al. Ann Intern Med. 2022 Apr.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Disclosures: Authors have disclosed no conflicts of interest. Forms can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L21-0791.

Comment on

References

    1. Mackey K , Kansagara D , Vela K . Update alert 7: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults [Letter]. Ann Intern Med. 2021;174:W25-W29. [PMID: ] doi: 10.7326/L20-1446 - DOI - PMC - PubMed
    1. Mackey K , Kansagara D , Vela K . Update alert 8: risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. Ann Intern Med. 2021;174:W54-W55. [PMID: ] doi: 10.7326/L21-0223 - DOI - PMC - PubMed
    1. Mackey K , King VJ , Gurley S , et al. Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults. A living systematic review. Ann Intern Med. 2020;173:195-203. [PMID: ] doi: 10.7326/M20-1515 - DOI - PMC - PubMed
    1. Duarte M , Pelorosso F , Nicolosi LN , et al. Telmisartan for treatment of Covid-19 patients: an open multicenter randomized clinical trial. EClinicalMedicine. 2021;37:100962. [PMID: ] doi: 10.1016/j.eclinm.2021.100962 - DOI - PMC - PubMed
    1. Geriak M , Haddad F , Kullar R , et al. Randomized prospective open label study shows no impact on clinical outcome of adding losartan to hospitalized COVID-19 patients with mild hypoxemia. Infect Dis Ther. 2021;10:1323-1330. [PMID: ] doi: 10.1007/s40121-021-00453-3 - DOI - PMC - PubMed

Substances